Dihexa
Nootropic peptide derived from angiotensin IV with a potency 10 million times greater than BDNF for the formation of new neural connections (synaptogenesis). Researched for Alzheimer's and cognitive decline. Extremely potent but with very limited clinical data.
Last updated:: 06/04/2026
Research Status
ANVISA (Brazil)
Not regulated
FDA (USA)
Not regulated
EMA (Europe)
Not regulated
Mechanism of Action
Dihexa binds to the HGF (Hepatocyte Growth Factor) / c-Met receptor, potentiating HGF signaling in the brain. This promotes synaptogenesis (formation of new synapses), neurogenesis, and neuronal survival. It is orally stable, which is rare for peptides.
Study Protocols
Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.
Neuroproteção / cognição
Oral ou Subcutânea (SC)Agonista do receptor HGF/c-Met. 10 milhões de vezes mais potente que BDNF in vitro. Melhora memória espacial em ratos. Sem dados clínicos em humanos.
Benefits
Potent synaptogenesis
Under researchA seminal study demonstrated 10^7 times greater potency than BDNF in forming new synapses in vitro. It restored cognitive function in rats with induced dementia.
View studyOral bioavailability
Under researchUnlike most peptides, it is stable and active when administered orally in animal models.
Risks and Side Effects
Theoretical oncological risk
High(Unknown)Activates the HGF/c-Met pathway, which is a known oncogene. Overactivation of this pathway is associated with tumor growth and metastasis. Long-term risk is completely unknown.
Zero human data
High(N/A)All evidence comes from a single laboratory (University of Washington). No published human studies.
Internet vs. Science
What people say online compared to the actual scientific evidence.
The most potent nootropic in existence
InconclusiveWhat they claim
Dihexa is 10 million times more potent than BDNF — the super peptide for the brain.
Actual evidence
The in vitro potency is real (published in a peer-reviewed journal), but in vitro potency does not equal clinical efficacy. Zero human studies. Real oncological risk via c-Met. Using an oncogene activator as a nootropic is extremely risky without safety data.
| Claim | O que dizem | Evidência real | Verdict |
|---|---|---|---|
| The most potent nootropic in existence | Dihexa is 10 million times more potent than BDNF — the super peptide for the brain. | The in vitro potency is real (published in a peer-reviewed journal), but in vitro potency does not equal clinical efficacy. Zero human studies. Real oncological risk via c-Met. Using an oncogene activator as a nootropic is extremely risky without safety data. | Inconclusive |
Studies and References (1)
McCoy AT, Benoist CC, Wright JW, et al. — ACS Medicinal Chemistry Letters (2013)
Dihexa demonstrou potência 10^7 vezes maior que BDNF para sinaptogênese in vitro e restaurou déficits cognitivos em ratos via ativação de HGF/c-Met.
PubMedImportant notice
This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.
Not Yet Available
This compound is still experimental and has not been approved for use. Sign up to be notified when it becomes available.